Founded at the end of 2024, AISRI grew out of a key internal incubation project of Tianzhihang, a listed company. Drawing on Tianzhihang’s extensive patented technologies and accumulated clinical data of surgical robots, AISRI focuses on building an intelligent diagnosis and treatment ecosystem centered on precise intraoperative imaging. It is committed to delivering efficient and intelligent treatment solutions that are minimally invasive, precise and personalized for patients, living up to its corporate vision: “With our expertise, we safeguard the beauty of life.”

The Innovation Center for Intelligent Medical Equipment and core manufacturing bases are located in Hefei and Beijing. Centered on cutting-edge technologies, unmet clinical needs and platform-based solutions, the company deeply integrates AI, imaging, robotics and other technologies.

Established for more than one year, AISRI has been certified as a technology-based small and medium-sized enterprise. It has filed over 20 patents (6 granted) and obtained 5 software copyrights. Its products have achieved commercial deployment in many top-tier tertiary hospitals across China.